Bio-Thera Solutions

688177 · SSE STAR Market

Public Market Listing

688177SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Bio-Thera Solutions are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
3Approved
2Phase 3 / Filed
2Phase 1–2 / Early
14Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
BAT1706(Avzivi)
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
BAT1806(Tofidence)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Phase 1/2
OX40Monoclonal antibody
Atopic Dermatitis
BAT2606No recent activity
Phase 1
IL-5Monoclonal antibody
Asthma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
VedastotugPhase 1/2Dermatitis, Atopic
Est. primary completion 2026-12-31 · NCT06094179 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
BAT5906Phase 3Diabetic Macular Edema (DME)
Est. primary completion 2027-04-30 · NCT07515079 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 December 2025Filing acceptedBAT5906NMPA accepts the marketing application for BAT5906 (velasitaximab) injection
CN, NMPA · Source ↗
21 August 2025Topline resultBAT5906BAT5906 nAMD Phase 3 vs ranibizumab (NCT05439629) met its primary endpoint
百奥泰生物制药股份有限公司 (Bio-Thera Solutions, 688177.SH) · Source ↗
27 May 2025Approvalustekinumab-hmny (Starjemza)FDA approves STARJEMZA (ustekinumab-hmny), a Stelara biosimilar
US, FDA · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$36M——$22Mreport ↗